Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MARTIN KORBLING and RICHARD E CHAMPLIN.
MARTIN KORBLING
Connection Strength
3.818
RICHARD E CHAMPLIN
  1. Peripheral blood progenitor cell transplantation: a replacement for marrow auto- or allografts. Stem Cells. 1996 Mar; 14(2):185-95.
    View in: PubMed
    Score: 0.140
  2. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44.
    View in: PubMed
    Score: 0.109
  3. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol. 2009 Jun; 84(6):335-7.
    View in: PubMed
    Score: 0.088
  4. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009 Jun; 15(6):718-23.
    View in: PubMed
    Score: 0.087
  5. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 Jun; 14(6):672-84.
    View in: PubMed
    Score: 0.082
  6. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood. 2008 Jun 15; 111(12):5530-6.
    View in: PubMed
    Score: 0.081
  7. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant. 2007 Apr; 13(4):469-77.
    View in: PubMed
    Score: 0.075
  8. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion. 2006 Oct; 46(10):1795-802.
    View in: PubMed
    Score: 0.073
  9. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma. 2006 Jul; 47(7):1290-4.
    View in: PubMed
    Score: 0.072
  10. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol. 2006 Jun; 133(5):533-7.
    View in: PubMed
    Score: 0.071
  11. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2005 Apr 01; 23(10):2240-7.
    View in: PubMed
    Score: 0.066
  12. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood. 1995 Mar 15; 85(6):1659-65.
    View in: PubMed
    Score: 0.066
  13. Umbilical cord blood-derived cells for tissue repair. Cytotherapy. 2005; 7(3):258-61.
    View in: PubMed
    Score: 0.065
  14. Designing an ethical policy for bone marrow donation by minors and others lacking capacity. Camb Q Healthc Ethics. 2004; 13(2):149-55.
    View in: PubMed
    Score: 0.060
  15. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004 Jan; 32(1):28-35.
    View in: PubMed
    Score: 0.060
  16. Adult stem cells and tissue repair. Bone Marrow Transplant. 2003 Aug; 32 Suppl 1:S23-4.
    View in: PubMed
    Score: 0.059
  17. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003 Mar; 31(6):459-65.
    View in: PubMed
    Score: 0.057
  18. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant. 2002 Nov; 30(10):661-3.
    View in: PubMed
    Score: 0.056
  19. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2002 Sep; 30(6):367-73.
    View in: PubMed
    Score: 0.055
  20. Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells. N Engl J Med. 2002 Mar 07; 346(10):738-46.
    View in: PubMed
    Score: 0.053
  21. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol. 2002 Mar; 13(3):450-9.
    View in: PubMed
    Score: 0.053
  22. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001 Dec 15; 98(13):3595-9.
    View in: PubMed
    Score: 0.052
  23. Controlled trial of filgrastim for acceleration of neutrophil recovery after allogeneic blood stem cell transplantation from human leukocyte antigen-matched related donors. Blood. 2001 Jun 01; 97(11):3405-10.
    View in: PubMed
    Score: 0.051
  24. Donor lymphocyte apheresis for adoptive immunotherapy compared with blood stem cell apheresis. J Clin Apher. 2001; 16(2):82-7.
    View in: PubMed
    Score: 0.049
  25. Cryofibrinogenemia and skin necrosis in a patient with diffuse large cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2000 Dec; 26(12):1343-5.
    View in: PubMed
    Score: 0.049
  26. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant. 2000 Sep; 26(6):615-20.
    View in: PubMed
    Score: 0.048
  27. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant. 2000 Jun; 25(11):1137-40.
    View in: PubMed
    Score: 0.047
  28. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol. 2000 Jun; 109(4):770-2.
    View in: PubMed
    Score: 0.047
  29. Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia. J Clin Oncol. 2000 May; 18(9):1831-6.
    View in: PubMed
    Score: 0.047
  30. High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. Cytotherapy. 2000; 2(2):105-10.
    View in: PubMed
    Score: 0.046
  31. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol. 1999 Nov; 10(11):1293-9.
    View in: PubMed
    Score: 0.045
  32. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation. Bone Marrow Transplant. 1999 Oct; 24(7):763-8.
    View in: PubMed
    Score: 0.045
  33. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood. 1999 Aug 15; 94(4):1465-70.
    View in: PubMed
    Score: 0.045
  34. Syngeneic blood stem cell transplantation for infectious mononucleosis-related aplastic anaemia. Br J Haematol. 1999 Jul; 106(1):159-61.
    View in: PubMed
    Score: 0.044
  35. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion. 1999 Jun; 39(6):555-60.
    View in: PubMed
    Score: 0.044
  36. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May; 10(5):527-32.
    View in: PubMed
    Score: 0.044
  37. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia. Bone Marrow Transplant. 1999 May; 23(10):977-81.
    View in: PubMed
    Score: 0.044
  38. Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system. Cytotherapy. 1999; 1(2):111-7.
    View in: PubMed
    Score: 0.043
  39. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998 Dec; 16(12):3803-9.
    View in: PubMed
    Score: 0.042
  40. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug; 16(8):2817-24.
    View in: PubMed
    Score: 0.041
  41. Blood stem cell procurement: donor safety issues. Bone Marrow Transplant. 1998 Jun; 21 Suppl 3:S35-9.
    View in: PubMed
    Score: 0.041
  42. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998 Mar; 16(3):986-93.
    View in: PubMed
    Score: 0.040
  43. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
    View in: PubMed
    Score: 0.040
  44. Identification of megakaryocyte precursors in peripheral blood stem cell collections from normal donors. J Clin Apher. 1998; 13(1):7-15.
    View in: PubMed
    Score: 0.040
  45. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997 Aug 01; 90(3):903-8.
    View in: PubMed
    Score: 0.039
  46. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15; 89(12):4531-6.
    View in: PubMed
    Score: 0.038
  47. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion. 1997 May; 37(5):507-12.
    View in: PubMed
    Score: 0.038
  48. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May; 97(2):466-73.
    View in: PubMed
    Score: 0.038
  49. Collection of peripheral blood stem cells from normal donors 60 years of age or older. Br J Haematol. 1997 May; 97(2):485-7.
    View in: PubMed
    Score: 0.038
  50. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 1997 Mar; 19(5):455-60.
    View in: PubMed
    Score: 0.038
  51. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. J Clin Oncol. 1997 Feb; 15(2):667-73.
    View in: PubMed
    Score: 0.037
  52. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol. 1997 Feb; 96(2):415-7.
    View in: PubMed
    Score: 0.037
  53. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Jan; 19(2):121-7.
    View in: PubMed
    Score: 0.037
  54. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 1996 Dec 27; 62(12):1806-10.
    View in: PubMed
    Score: 0.037
  55. Delayed effects of rhG-CSF mobilization treatment and apheresis on circulating CD34+ and CD34+ Thy-1dim CD38- progenitor cells, and lymphoid subsets in normal stem cell donors for allogeneic transplantation. Bone Marrow Transplant. 1996 Dec; 18(6):1073-9.
    View in: PubMed
    Score: 0.037
  56. Peripheral blood stem cell apheresis in normal donors: the neglected side. Blood. 1996 Nov 01; 88(9):3663-4.
    View in: PubMed
    Score: 0.037
  57. Allogeneic peripheral blood stem cell transplantation using normal patient-related pediatric donors. Bone Marrow Transplant. 1996 Nov; 18(5):885-90.
    View in: PubMed
    Score: 0.037
  58. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood. 1996 Oct 15; 88(8):2819-25.
    View in: PubMed
    Score: 0.037
  59. Rapid debulking and CD34 enrichment of filgrastim-mobilized peripheral blood stem cells by semiautomated density gradient centrifugation in a closed system. J Hematother. 1996 Oct; 5(5):497-502.
    View in: PubMed
    Score: 0.037
  60. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 12; 22(12):2159-2164.
    View in: PubMed
    Score: 0.036
  61. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
    View in: PubMed
    Score: 0.036
  62. Clinical toxicity and laboratory effects of granulocyte-colony-stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures. Transfusion. 1996 Jul; 36(7):590-5.
    View in: PubMed
    Score: 0.036
  63. Transient neutropenia in normal donors after G-CSF mobilization and stem cell apheresis. Br J Haematol. 1996 Jul; 94(1):155-8.
    View in: PubMed
    Score: 0.036
  64. Duration of filgrastim mobilization and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation. Br J Haematol. 1996 Jun; 93(4):940-2.
    View in: PubMed
    Score: 0.036
  65. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995 Dec 01; 86(11):4337-43.
    View in: PubMed
    Score: 0.034
  66. Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood. 1995 Oct 01; 86(7):2842-8.
    View in: PubMed
    Score: 0.034
  67. With first successful allogeneic transplantations of apheresis-derived hematopoietic progenitor cells reported, can the recruitment of volunteer matched, unrelated stem cell donors be expanded substantially? Blood. 1995 Aug 01; 86(3):1235.
    View in: PubMed
    Score: 0.034
  68. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma. 2015 Mar; 56(3):711-5.
    View in: PubMed
    Score: 0.031
  69. Large-scale preparation of highly purified, frozen/thawed CD34+, HLA-DR- hematopoietic progenitor cells by sequential immunoadsorption (CEPRATE SC) and fluorescence-activated cell sorting: implications for gene transduction and/or transplantation. Bone Marrow Transplant. 1994 May; 13(5):649-54.
    View in: PubMed
    Score: 0.031
  70. Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission. Cancer. 2013 Sep 15; 119(18):3318-25.
    View in: PubMed
    Score: 0.029
  71. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.
    View in: PubMed
    Score: 0.028
  72. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. 2012 Jun 28; 119(26):6373-8.
    View in: PubMed
    Score: 0.027
  73. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011 Nov 24; 118(22):5957-64.
    View in: PubMed
    Score: 0.026
  74. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009 Oct 27; 88(8):1019-24.
    View in: PubMed
    Score: 0.023
  75. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010 Mar; 45(3):429-36.
    View in: PubMed
    Score: 0.022
  76. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009 Apr 30; 113(18):4144-52.
    View in: PubMed
    Score: 0.021
  77. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol. 2008 Sep; 142(5):786-92.
    View in: PubMed
    Score: 0.021
  78. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol. 2007 May; 137(4):355-63.
    View in: PubMed
    Score: 0.019
  79. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant. 2006 Sep; 38(6):421-6.
    View in: PubMed
    Score: 0.018
  80. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol. 1995 May; 13(5):1096-102.
    View in: PubMed
    Score: 0.017
  81. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994 May 15; 83(10):3068-76.
    View in: PubMed
    Score: 0.015
  82. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004 Aug 01; 104(3):857-64.
    View in: PubMed
    Score: 0.015
  83. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001 Jun; 27(12):1221-5.
    View in: PubMed
    Score: 0.013
  84. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2001; 7(10):568-75.
    View in: PubMed
    Score: 0.012
  85. High-dose melphalan and allogeneic peripheral blood stem cell transplantation for treatment of early relapse after allogeneic transplant. Bone Marrow Transplant. 2000 Aug; 26(3):333-8.
    View in: PubMed
    Score: 0.012
  86. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 1999 Oct; 35(3-4):317-24.
    View in: PubMed
    Score: 0.011
  87. Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant. 1997 Aug; 3(3):150-6.
    View in: PubMed
    Score: 0.010
  88. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15346-51.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.